Health & Environmental Research Online (HERO)


Print Feedback Export to File
3225106 
Journal Article 
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer 
Nakamura, M; Yamada, Y; Muro, Kei; Takahashi, K; Baba, H; Sasaki, Y; Komatsu, Y; Satoh, T; Mishima, H; Watanabe, M; Sakata, Yuh; Morita, S; Shimada, Y; Sugihara, K 
2015 
Yes 
Future Oncology
ISSN: 1479-6694 
11 
10 
1471-1478 
WOS:000354556100005 
A combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) plus bevacizumab has been widely used for the first-line chemotherapy of metastatic colorectal cancer (mCRC). S-1 is an oral fluoropyrimidine preparation that combines tegafur, a prodrug of 5-fluorouracil, with two modulators. Several studies of combination chemotherapy with oxaliplatin plus S-1 (SOX) conducted in Asia have reported promising efficacy and safety in patients with mCRC, suggesting the potential to replace mFOLFOX6. The SOFT trial (JapicCTI-090699) was a randomized Phase III trial designed to evaluate the noninferiority of SOX plus bevacizumab to mFOLFOX6 plus bevacizumab in patients with mCRC. This review summarizes the drug concept of S-1 and the results of clinical trials of S-1 and SOX in CRC and presents an overview of the SOFT trial. 
DPD inhibitory fluoropyrimidine; metastatic colorectal cancer; oxaliplatin; S-1; SOFT trial; SOX